Drugs / hAECs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03223454 | Oct 2017 → Sep 2019 | Asherman syndrome | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03764228 | Jul 2020 → Jul 2021 | acute graft versus host disease | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT03207412 | Dec 2017 → Jul 2019 | primary ovarian failure | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAECs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03207412 ↗ |
| Known as | Human amniotic epithelial cells | “Human amniotic epithelial cells (hAECs) are derived from human amniotic epithelium.” NCT03223454 ↗ |
| Modality | Cell therapy | “provide a new cell therapy against infertility” NCT03207412 ↗ |
| Route | Other | “minimally invasive implantation” NCT03207412 ↗ |